Navigation Links
Crux Successfully Completes Funding for Advanced Filter for PE Prevention
Date:6/6/2011

MENLO PARK, Calif., June 6, 2011 /PRNewswire/ -- Crux Biomedical Inc., a developer of an advanced implantable vena cava filter (VCF), announced the successful completion a $12.0MM investment round.  The round was led by Three Arch Partners, which was joined by current investors, Alloy Ventures and Emergent Medical Partners.

Vena cava filters, which were first introduced in the late 60's, are designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). During the last 10 years, VCFs have been designed to be placed on a permanent basis or  retrieved  at a later date. The Crux vena cava filter has been designed to address the complications seen with current VCFs. "The Crux device represents the first significant design innovation since vena cava filters were introduced. Its design represents a radical departure from the traditional conical design and for the first time combines ease of placement with enhanced retrievability," stated Bill Harrington, M.D. and partner at Three Arch Partners.

Crux Biomedical initiated its pivotal Retrieve 2 U.S. clinical trial at 18 centers of excellence in the second half of 2010.  The Company is simultaneously conducting clinical evaluations in both Europe and Australia/New Zealand and expects to complete patient enrollment shortly. "We are very pleased with the interim success of our ongoing clinicals in both the U.S. and abroad," states Crux CEO, Mel Schatz. He continued, "It has been rewarding to see the physician enthusiasm for our filter and their belief it will prove to be an advance in the management of patients at risk for a PE." Crux anticipates commercial availability in the first half of 2012.

Recent reports have cited safety concern with currently available VCFs related to both the incidence of filter fracturing and associated challenges of retrieving the filters. The Crux VCF has been designed to minimize these problems. "We are very excited to be part of the clinical development of a novel VCF that offers a potential safety advantage over current technologies, with the flexibility of bidirectional placement and retrieval," stated Doug Kelly, M.D. and partner at Alloy Ventures.

There are an estimated 200,000 deaths attributed to PE in the United States alone each year. The American Public Health Association and the CDC have pointed out that deaths attributed to PE exceed the combined deaths per annum due to breast cancer, AIDS and highway fatalities.  Experts cite the increase in PE incidence to more complex surgeries, trauma, expanded use of chemotherapeutics and an aging population.

Crux is a privately held medical device company, founded in 2004 by Tom Fogarty, M.D. and specializes in minimally invasive vascular devices. The Company is headquartered in Menlo Park, California.


'/>"/>
SOURCE Crux Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Successfully Completes Acquisition of Celera
2. Fredericksburg Nephrology Associates, Inc., Successfully Attests to Meaningful Use Using Acumen EHR
3. Siemens Applauds First Health System Customers to Successfully Attest to Meaningful Use
4. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
5. Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
6. American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
7. Mumbai Successfully Hosts Largest Ever India Events Cluster With CPhI, P-MEC, ICSE and BioPh India 2010
8. EDDA Technology Successfully Installs IQQA®-Liver at Mayo Clinic in Arizona
9. Hotspur Technologys Novel 3-in-1 Angioplasty Balloon Successfully Achieves First Commercial Deployment
10. Opto Circuits Successfully Completes Acquisition of Cardiac Science
11. Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices ... ... The full report suite on the ... fluid external drainage systems, intracranial pressure monitoring devices, detachable coils, ...
(Date:11/30/2016)... Nov. 30, 2016 Varian Medical Systems (NYSE: ... America,s Most JUST Company in the Healthcare Equipment and ... magazine,s inaugural "JUST 100 List." The rankings are ... surveys ever conducted on attitudes towards corporate behavior, involving ... list ranks U.S companies against their peers within 32 ...
Breaking Medicine Technology:
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ‘Tis the ... winners of $1,000 each from the National Family Partnership and the Drug Enforcement Administration ... who decorated their homes and the 10 winning schools who decorated their campuses with ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my toothbrush ... N.J. "I thought that there had to be a way to prevent this mess, ... to prevent saliva and toothpaste from running down the brush handle onto the hand ...
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new residential ... treatment for girls with mental health issues such as severe anxiety, depression, bi-polar ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
Breaking Medicine News(10 mins):